Table 3 Chemotherapy data collected from relevant articles for three main parasitic diseases in China
From: Research gaps for three main tropical diseases in the People’s Republic of China
Disease | Article (n) | Clinical trial for MOH Recommended drug | Drug development | |||||
|---|---|---|---|---|---|---|---|---|
Drug’s name (n) | Cure rates (%) | Population | Labwork (n) | Clinical trial (n) | Basic science | Marketization | ||
Malaria | 51* | Dihydroartemisinin (31) | 70%-100% | 104 (15–1205) | 50 | 0 | 50/50 | 0/50 |
Artemether (30) | 79.8%-100% | |||||||
Piperaquine (19) | 80%-100% | |||||||
Artesunate (18) | 90.7%-100% | |||||||
Chloroquine (9) | 62.8%-100% | |||||||
Primaquine (9) | 85.5%-100% | |||||||
Artemether-lumefantrine (1) | 82.50% | |||||||
Schistosomiasis | 22 | Praziquantel (22) | 74.7%-100% | 221 (33–615) | 42 | 0 | 42/42 | 0/42 |
Echinococcosis | 11* | Albendazole emulsion (7) | 57.1%-83.1% | 95 (36–264) | 11 | 9 | 11/20 | 9/20 |
Albendazole tablet (6) | 15.8%-31.3% | 57 (24–108) | ||||||